The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Cardinal Health, Inc., Pharmaceutical Technologies and Services division
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
Alcon, Inc.
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
American Dental Partners, Inc.
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
TNS, Inc.
Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors
Rofin-Sinar Technologies, Inc.
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Blue Owl Technology Finance Corp. II (“OTF II”)
Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF